Sarcoma (Soft Tissue Sarcoma)

10281  relevant articles (419 outcomes, 1305 trials/studies) found for this Disease

Soft Tissue Sarcoma; Sarcomas; Soft Tissue Sarcomas; Spindle Cell Sarcoma; Epithelioid Sarcoma; Epithelioid Sarcomas; Sarcomas, Epithelioid; Sarcomas, Soft Tissue; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; Sarcoma, Epithelioid; Sarcoma, Soft Tissue; Sarcoma, Spindle Cell

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Melanoma (Melanoma, Malignant)
3.	Sarcoma (Soft Tissue Sarcoma)
4.	Neoplasm Metastasis (Metastasis)
5.	Carcinoma (Carcinomatosis)

Experts

1.	Verweij, J: 14 articles (07/2005 - 01/2000)
2.	Pollock, Raphael E: 13 articles (09/2008 - 04/2002)
3.	Blay, Jean-Yves: 11 articles (02/2008 - 01/2004)
4.	Judson, I: 11 articles (09/2006 - 01/2000)
5.	Maki, Robert G: 10 articles (11/2007 - 08/2002)
6.	Nielsen, O S: 10 articles (04/2007 - 01/2000)
7.	Benjamin, Robert S: 9 articles (03/2008 - 09/2002)
8.	Eggermont, Alexander M M: 9 articles (12/2007 - 01/2002)
9.	Blay, J Y: 9 articles (04/2007 - 01/2000)
10.	Le Cesne, A: 8 articles (04/2008 - 07/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Sarcoma:

1.	Doxorubicin (Adriamycin)FDA LinkGeneric 04/01/1981 - "Radionuclide cineangiography was used to evaluate 32 patients who sustained long-term remission of soft tissue sarcoma after adjuvant therapy with a cumulative doxorubicin dose from 480 to 550 mg/m body surface area" 05/01/2003 - "From 1988 to 2000, we have investigated in a pilot study and then in a phase II study the efficacy of a concomitant doxorubicin radiotherapy treatment in patients with advanced and/or metastatic soft tissue sarcomas (STS)" 02/15/2001 - "The efficacy of doxorubicin in the treatment of vaccine-associated sarcomas is uncertain." 04/01/1987 - "Extending the doxorubicin dosage to its tolerable limits did not appear to result in improved efficacy in patients with metastatic mixed mesodermal uterine sarcomas" 05/01/1978 - "Remission of orbital sarcoma in a dog, using doxorubicin therapy." Order ALL the reference details at left...
2.	IfosfamideFDA LinkGeneric 11/01/1998 - "The aim of the present study was to assess the activity of ifosfamide with a new schedule for patients with advanced soft tissue sarcoma failing to achieve remission or relapsing following anthracycline-containing regimens; it was attempted to individualize dosages and prevent excessive toxicity" 08/01/2000 - "Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma." 01/01/2008 - "STUDY DESIGN AND METHODS: A total of 19 patients received high-dose ifosfamide for soft tissue sarcoma during a 4-year period at our medical centre" 03/01/2006 - "Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas." 12/01/2004 - "We evaluated efficacy and toxicity of high-dose ifosfamide in the patients with recurrent or advanced sarcoma in this study" Order ALL the reference details at left...
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/01/1992 - "In this study, we investigated the effect of tumor necrosis factor-alpha (TNF alpha) on the generation and function of IVS cells utilized in adoptive immunotherapy of the murine MCA 106 sarcoma" 04/15/1989 - "Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study." 12/01/2007 - "The addition of tumor necrosis factor-alpha (TNF-alpha) to this treatment approach contributed to a major step forward in the treatment of locally advanced extremity soft tissue sarcoma (STS)" 04/01/2006 - "CONCLUSIONS: Adjuvant EBRT reduces the risk for local recurrence after delayed resection in soft tissue sarcoma patients treated with ILP and tumor necrosis factor and is indicated when resection margins are close or microscopically positive" 07/01/2005 - "BACKGROUND: The optimal dose of TNF-alpha delivered by isolated limb perfusion (ILP) in patients with locally advanced soft tissue sarcoma is still unknown" Order ALL the reference details at left...
4.	Melphalan (Alkeran)FDA Link 03/15/1997 - "CONCLUSIONS: The combination of high dose rTNF-alpha and melphalan given via ILP appears to be effective in patients with advanced soft tissue sarcoma confined to the limb, achieving a high response rate and limb preservation." 05/01/2001 - "CONCLUSIONS: HILP with melphalan is a safe and effective treatment option for selected patients with locally advanced and unresectable extremity sarcomas" 03/15/1997 - "The purpose of the current study was to assess the role of rTNF-alpha and melphalan administered via ILP in patients with soft tissue sarcoma" 07/01/2003 - "TNFalpha was approved in Europe after a multicentre trial in patients with locally advanced soft-tissue sarcomas, deemed unresectable by an independent review committee; the response rate to isolated limb perfusion with TNFalpha plus melphalan was 76% and the limb was saved in 71% of patients" 01/01/2003 - "Perfusion setting aimed at limb preservation with rhTNF plus melphalan is currently used in sarcoma patients" Order ALL the reference details at left...
5.	Cyclophosphamide (Cytoxan)FDA Link 07/01/2007 - "Low dose radiation increased the therapeutic efficacy of cyclophosphamide on S(180) sarcoma bearing mice." 12/01/2003 - "This article reports the experiment studies on treating the S-180 sarcomas of KM mice with high-intensity electric pulse and antitumor drug (cyclophosphamide)" 11/01/1987 - "In vitro studies revealed that Kupffer cell tumoricidal activity against sarcoma was increased (p less than 0.05) following glucan and cyclophosphamide" 04/01/1963 - "Clinical trials with cyclophosphamide in children with soft tissue sarcoma." 01/01/2004 - "Total extract, polar and non-polar extracts, and their formulations, prepared from medicinal plants mentioned in Ayurveda, namely, Withania somnifera (Linn Dunal) (Solanaceae), Tinospora cordifolia (Miers) (Menispermaceae), and Asparagus racemosus (Willd.) (Liliaceae), exhibited various immunopharmacological activities in cyclophosphamide (CP)-treated mouse ascitic sarcoma" Order ALL the reference details at left...
6.	Cisplatin (Platino)FDA LinkGeneric 12/01/2006 - "The aim of our study was to evaluate feasibility and therapeutic potential of electrogene therapy with p53 alone or combined with electrochemotherapy using cisplatin on two murine sarcomas with different p53 status" 07/01/2005 - "The objectives of this study were to investigate the pharmacokinetics of cisplatin (CDDP) and the thermal dose, toxicity, and feasibility of hyperthermic isolated regional perfusion (HIRP) with CDDP for bone and soft-tissue sarcomas of the lower limb" 07/01/1986 - "The M5076 sarcoma was used to evaluate the antitumor activities of several analogs of Platinol presently undergoing clinical trials" 02/01/1986 - "Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study." 11/01/1979 - "Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study." Order ALL the reference details at left...
7.	MethylcholanthreneIBA 06/15/1990 - "Protection from rhTNF toxicity was not associated with any reduction in the therapeutic efficacy of rhTNF against methylcholanthrene-induced sarcomas in either s.c" 03/01/1998 - "In this study we examined 63 methylcholanthrene (MCA)-induced sarcomas from C57BL/6N x C3H/HeN F1 (BCF1) or C3H/HeN x C57BL/6N F1 (CBF1) mice for p53 gene mutations and loss of heterozygosity (LOH) of chromosome 11" 12/01/1996 - "EFFICACY STUDY: On day 0, 41 rats received an intravenous injection of 5 x 10(6) methylcholanthrene induced sarcoma cells" 12/01/1995 - "The present study indicates a possible involvement of K-ras mutation and c-myc amplification in induction of genetic instability in methylcholanthrene-induced mouse sarcomas." 02/15/1994 - "We have utilized a newly developed culture system to study the properties of antitumor CD4+ T-cells relevant to the rejection of syngeneic methylcholanthrene sarcomas" Order ALL the reference details at left...
8.	Interleukin-2 (IL2)IBA 03/01/1999 - "Previously we demonstrated that surgical minimal residual tumour disease (SMRTD) could be effectively cured when murine Mc12 sarcoma had been resected and the operated mice were treated with irradiated Mc12 sarcoma cells engineered to secrete IL-2" 11/01/2004 - "In addition, expression of interleukin-2 receptorbeta, located in 22q, was revealed by immunohistochemical method in six cases with gain of 22q, suggesting it may play a role in epithelioid sarcoma tumorigenesis." 04/01/2001 - "Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients" 01/01/2000 - "The IL-2 gene-transduced sarcoma has previously been utilized as an irradiated, genetically modified tumour vaccine" 03/02/1999 - "In three separate approaches using a weakly immunogenic sarcoma (MCA-207), the systemic administration of nontoxic doses of recombinant IL-2 (20,000 and 40,000 IU/dose) was capable of mediating significant increases in the potency of DC-based immunizations" Order ALL the reference details at left...
9.	DNA (Deoxyribonucleic Acid)IBA